Which has preferable valuation and earnings, IPHA or FDMT?

Innate Pharma has higher earnings, but lower revenue than 4D Molecular Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.59 -$55.64M N/A N/A 4D Molecular Therapeutics $85.21M 7.98 -$140.11M -$2.57 N/A

Does the media favor IPHA or FDMT?

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Innate Pharma. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 1 mentions for Innate Pharma. 4D Molecular Therapeutics' average media sentiment score of 0.36 beat Innate Pharma's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 4D Molecular Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, DRUG or IPHA?

Bright Minds Biosciences has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Innate Pharma $10.19M 16.59 -$55.64M N/A N/A

Is DRUG or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Innate Pharma N/A N/A N/A

Does the media refer more to DRUG or IPHA?

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 1 articles in the media. Bright Minds Biosciences' average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, IPHA or PRME?

Innate Pharma has higher revenue and earnings than Prime Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.59 -$55.64M N/A N/A Prime Medicine $4.63M 150.97 -$201.14M -$1.23 N/A

Which has higher valuation & earnings, IPHA or DNA?

Innate Pharma has higher earnings, but lower revenue than Ginkgo Bioworks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.59 -$55.64M N/A N/A Ginkgo Bioworks $170.15M 3.98 -$312.76M -$5.36 N/A

Do analysts prefer IPHA or AVTE?

Innate Pharma currently has a consensus target price of $5.00, indicating a potential upside of 177.78%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, IPHA or AVTE?

Innate Pharma has higher revenue and earnings than Aerovate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.59 -$55.64M N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is IPHA or AVTE more profitable?

Innate Pharma's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Innate Pharma (IPHA) Competitors

$1.82 +0.02 (+1.17%)

As of 07/2/2026 04:00 PM Eastern

Compare

IPHA vs. FDMT, DRUG, PRME, DNA, and AVTE

Should you buy Innate Pharma stock or one of its competitors? MarketBeat compares Innate Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innate Pharma include 4D Molecular Therapeutics (FDMT), Bright Minds Biosciences (DRUG), Prime Medicine (PRME), Ginkgo Bioworks (DNA), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Innate Pharma compare to 4D Molecular Therapeutics?

Innate Pharma (NASDAQ:IPHA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Innate Pharma has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Innate Pharma's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Innate Pharma has higher earnings, but lower revenue than 4D Molecular Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A
4D Molecular Therapeutics	$85.21M	7.98	-$140.11M	-$2.57	N/A

Innate Pharma has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the broader market.

Innate Pharma presently has a consensus price target of $5.00, indicating a potential upside of 177.78%. 4D Molecular Therapeutics has a consensus price target of $29.88, indicating a potential upside of 129.81%. Given Innate Pharma's higher possible upside, equities analysts clearly believe Innate Pharma is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Innate Pharma. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 1 mentions for Innate Pharma. 4D Molecular Therapeutics' average media sentiment score of 0.36 beat Innate Pharma's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Innate Pharma beats 4D Molecular Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Innate Pharma compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Innate Pharma's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Innate Pharma	N/A	N/A	N/A

Bright Minds Biosciences currently has a consensus price target of $143.83, suggesting a potential upside of 112.77%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 177.78%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Bright Minds Biosciences has a beta of -5.34, indicating that its share price is 634% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Bright Minds Biosciences has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 1 articles in the media. Bright Minds Biosciences' average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Innate Pharma beats Bright Minds Biosciences on 6 of the 11 factors compared between the two stocks.

How does Innate Pharma compare to Prime Medicine?

Innate Pharma (NASDAQ:IPHA) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Innate Pharma has higher revenue and earnings than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A
Prime Medicine	$4.63M	150.97	-$201.14M	-$1.23	N/A

In the previous week, Prime Medicine had 7 more articles in the media than Innate Pharma. MarketBeat recorded 8 mentions for Prime Medicine and 1 mentions for Innate Pharma. Prime Medicine's average media sentiment score of 1.00 beat Innate Pharma's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Innate Pharma	Neutral
Prime Medicine	Positive

Innate Pharma has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market.

Innate Pharma currently has a consensus target price of $5.00, indicating a potential upside of 177.78%. Prime Medicine has a consensus target price of $7.53, indicating a potential upside of 94.61%. Given Innate Pharma's higher possible upside, analysts plainly believe Innate Pharma is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Innate Pharma has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Innate Pharma's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Innate Pharma and Prime Medicine tied by winning 7 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Ginkgo Bioworks?

Innate Pharma (NASDAQ:IPHA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Innate Pharma has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Innate Pharma's return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Innate Pharma has higher earnings, but lower revenue than Ginkgo Bioworks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A

Innate Pharma presently has a consensus price target of $5.00, indicating a potential upside of 177.78%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential downside of 17.99%. Given Innate Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Innate Pharma is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Innate Pharma had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 1 mentions for Innate Pharma and 0 mentions for Ginkgo Bioworks. Innate Pharma's average media sentiment score of 0.00 equaled Ginkgo Bioworks'average media sentiment score.

Company	Overall Sentiment
Innate Pharma	Neutral
Ginkgo Bioworks	Neutral

Summary

Innate Pharma beats Ginkgo Bioworks on 10 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Aerovate Therapeutics?

Innate Pharma (NASDAQ:IPHA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Innate Pharma has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, Innate Pharma had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Innate Pharma and 0 mentions for Aerovate Therapeutics. Innate Pharma's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Innate Pharma	Neutral
Aerovate Therapeutics	Neutral

0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Innate Pharma currently has a consensus target price of $5.00, indicating a potential upside of 177.78%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Innate Pharma's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Innate Pharma has higher revenue and earnings than Aerovate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Innate Pharma beats Aerovate Therapeutics on 11 of the 12 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$169.06M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	16.59	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-6.92	8.66	10.96	6.46
Net Income	-$55.64M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.56%	3.39%	2.12%	1.69%
1 Month Performance	5.26%	10.81%	5.25%	3.81%
1 Year Performance	-1.15%	62.61%	33.29%	23.90%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	2.1255 of 5 stars	$1.80 flat	$5.00 +177.8%	-1.2%	$169.06M	$10.19M	N/A	220	Positive News Gap Up
FDMT 4D Molecular Therapeutics	1.8964 of 5 stars	$13.30 +3.3%	$29.88 +124.6%	+217.5%	$673.32M	$85.21M	N/A	120	News Coverage High Trading Volume
DRUG Bright Minds Biosciences	2.1481 of 5 stars	$70.20 +1.5%	$143.83 +104.9%	+138.9%	$673.27M	N/A	N/A	N/A	News Coverage Analyst Upgrade
PRME Prime Medicine	2.9433 of 5 stars	$3.69 -0.8%	$7.53 +104.1%	N/A	$671.90M	$4.63M	N/A	N/A	Positive News Analyst Revision
DNA Ginkgo Bioworks	0.3858 of 5 stars	$9.94 -2.7%	$8.50 -14.5%	-18.1%	$666.96M	$170.15M	N/A	640

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. FDMT, DRUG, PRME, DNA, and AVTE

How does Innate Pharma compare to 4D Molecular Therapeutics?

Summary

How does Innate Pharma compare to Bright Minds Biosciences?

Summary

How does Innate Pharma compare to Prime Medicine?

Summary

How does Innate Pharma compare to Ginkgo Bioworks?

Summary

How does Innate Pharma compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. FDMT, DRUG, PRME, DNA, and AVTE

How does Innate Pharma compare to 4D Molecular Therapeutics?

Do insiders and institutionals believe in IPHA or FDMT?

Is IPHA or FDMT more profitable?

Which has preferable valuation and earnings, IPHA or FDMT?

Which has more risk & volatility, IPHA or FDMT?

Do analysts rate IPHA or FDMT?

Does the media favor IPHA or FDMT?

Summary

How does Innate Pharma compare to Bright Minds Biosciences?

Do institutionals and insiders have more ownership in DRUG or IPHA?

Is DRUG or IPHA more profitable?

Do analysts prefer DRUG or IPHA?

Which has more volatility & risk, DRUG or IPHA?

Which has higher valuation and earnings, DRUG or IPHA?

Does the media refer more to DRUG or IPHA?

Summary

How does Innate Pharma compare to Prime Medicine?

Which has higher earnings and valuation, IPHA or PRME?

Does the media refer more to IPHA or PRME?

Which has more risk & volatility, IPHA or PRME?

Do analysts rate IPHA or PRME?

Do institutionals & insiders believe in IPHA or PRME?

Is IPHA or PRME more profitable?

Summary

How does Innate Pharma compare to Ginkgo Bioworks?

Which has more risk & volatility, IPHA or DNA?

Is IPHA or DNA more profitable?

Which has higher valuation & earnings, IPHA or DNA?

Do analysts prefer IPHA or DNA?

Do institutionals and insiders believe in IPHA or DNA?

Does the media favor IPHA or DNA?

Summary

How does Innate Pharma compare to Aerovate Therapeutics?

Which has more volatility & risk, IPHA or AVTE?

Does the media refer more to IPHA or AVTE?

Do insiders and institutionals believe in IPHA or AVTE?

Do analysts prefer IPHA or AVTE?

Is IPHA or AVTE more profitable?

Which has preferable earnings and valuation, IPHA or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools